Bristol Myers Squibb’s Zeposia launches into crowded MS market

Bristol Myers Squibb’s Zeposia launches into crowded MS market

When Bristol Myers Squibb nabbed Celgene’s long-sought FDA nod for multiple sclerosis drug Zeposia, the COVID-19 pandemic was in full swingnot the ideal time for a launch. Now, the company thinks the…
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *